Syros Pharmaceuticals Inc (SYRS) Stock Price, Trades & News

Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Financial Strength

	Name	Current	Vs Industry		Vs History

Growth Rank

	Name	Current	Vs Industry		Vs History

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	73.31
	9-Day RSI	61.61
	14-Day RSI	57.56
	3-1 Month Momentum %	-50
	6-1 Month Momentum %	-50
	12-1 Month Momentum %	-95.45

Liquidity Ratio

	Name	Current	Vs Industry		Vs History

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History

Profitability Rank

	Name	Current	Vs Industry		Vs History
	FCF Margin %	-25920.73
	OCF Margin %	-25910.88

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	EV-to-EBIT	-0.02
	EV-to-EBITDA	-0.02
	EV-to-Revenue	5.08
	EV-to-Forward-Revenue	3.25
	EV-to-FCF	-0.02
	Earnings Yield (Greenblatt) %	-5000
	FCF Yield %	-909581.82

Financials

Annual Quarterly TTM

SYRS's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with OTCPK:SYRS

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Syros Pharmaceuticals Inc Executives

Details

GF Value™

SYRS

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected issues with SYRS. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	0.386
	EPS (TTM) ($)	-3.07
	Beta	3.3158
	3-Year Sharpe Ratio	0.35
	3-Year Sortino Ratio	0.84
	Volatility %	460.13
	14-Day RSI	57.56
	14-Day ATR ($)	0.000197
	20-Day SMA ($)	0.000255
	12-1 Month Momentum %	-95.45
	52-Week Range ($)	0.0001 - 0.02
	Shares Outstanding (Mil)	26.83

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	0
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Syros Pharmaceuticals Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Syros Pharmaceuticals Inc Stock Events

Financials Calendars

Event	Date	Price ($)
Fourth quarter earnings results for 2026	2027-02-02	In 146 days
Fourth quarter earnings conference call for 2026	2027-02-02	In 146 days
Third quarter earnings conference call for 2026	2026-11-13 08:30	In 66 days
Third quarter earnings results for 2026	2026-11-13	In 65 days
Second quarter earnings conference call for 2026	2026-09-11	In 2 days
Second quarter earnings results for 2026	2026-09-11	In 2 days
General meeting for 2025	2026-09-08	0.00 (+0.00%)
Second quarter earnings conference call for 2026	2026-08-14	0.00 (+0.00%)
Second quarter earnings results for 2026	2026-08-14	0.00 (+0.00%)
First quarter earnings conference call for 2026	2026-05-15	0.00 (+0.00%)

Show

Entries

Syros Pharmaceuticals Inc Frequently Asked Questions

What is Syros Pharmaceuticals Inc(SYRS)'s stock price today?

The current price of SYRS is $0.00. The 52 week high of SYRS is $0.02 and 52 week low is $0.00.

When is next earnings date of Syros Pharmaceuticals Inc(SYRS)?

The next earnings date of Syros Pharmaceuticals Inc(SYRS) is .

Does Syros Pharmaceuticals Inc(SYRS) pay dividends? If so, how much?

Syros Pharmaceuticals Inc(SYRS) does not pay dividend.

Guru Commentaries on OTCPK:SYRS

No fund manager commentary yet.

Browse all fund letters →

Press Release

	Subject	Date
	Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration	2025-02-28
	Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression	2024-11-12
	Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update	2024-10-31
	Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024	2024-10-24
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS	2024-09-25
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS	2024-09-17
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS	2024-09-09
	Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings	2024-09-04
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS	2024-09-03
	Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged	2024-09-03

10/Page

Articles on Syros Pharmaceuticals Inc

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.